RSS

Catalent Biologics

Global provider of advanced delivery technologies and development solutions, Catalent, and clinical-stage biotechnology company, Vaccinex, have signed an agreement for the development of an antibody drug conjugate (ADC) to be used against cancer Read more

News

Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics for the development and manufacture of a lead therapeutic candidate for the treatment of solid tumours. Read more

News